Advanced search

Online first
Invited Review Article
Published online: 2025-02-14

open access

View PDF Download PDF file
Page views 249
Article views/downloads 184
Get Citation

Connect on Social Media

Connect on Social Media

Role of neuroinflammation factors as potential biomarkers of epilepsy: a narrative review

Marta Zawadzka1, Marta Pietruszka1, Magdalena Krygier1, Maria Mazurkiewicz-Bełdzińska1
DOI: 10.5603/pjnns.102426
Pubmed: 39950421

Abstract

Epilepsy is a common neurological condition with a significant socioeconomic impact. Approximately one in three patients is resistant to the available therapies, and the mechanisms of this resistance are often unclear. Neuroinflammation, recognised as a potential cause of drug-resistant epilepsy, plays a key role in modulating synaptic transmission and hyperexcitability.

In this narrative review, we explore the molecular basis of neuroinflammation in epilepsy and its potential as a source of biomarkers for diagnosis and treatment. Evidence from human and animal studies indicates a strong association between neuroinflammation and epilepsy, with significant involvement of pro-inflammatory molecules and blood-brain barrier dysfunction. We highlight the roles of microglia, astrocytes and inflammatory molecules in epilepsy, suggesting that targeted anti-inflammatory therapies could be promising for treatment. Further research is needed to fully understand the role of neuroinflammation in epilepsy and to develop new therapeutic approaches.

Keywords: neuroinflammationblood-brain barriercytokineepilepsyseizure

Article available in PDF format

View PDF Download PDF file

References

  1. Perucca E, Perucca P, White HS, et al. Drug resistance in epilepsy. Lancet Neurol. 2023; 22(8): 723–734.
    CrossRefPubMed
  2. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010; 51(6): 1069–1077.
    CrossRefPubMed
  3. Löscher W, Potschka H, Sisodiya SM, et al. Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options. Pharmacol Rev. 2020; 72(3): 606–638.
    CrossRefPubMed
  4. Alvim MKM, Morita-Sherman ME, Yasuda CL, et al. Inflammatory and neurotrophic factor plasma levels are related to epilepsy independently of etiology. Epilepsia. 2021; 62(10): 2385–2394.
    CrossRefPubMed
  5. Campos-Bedolla P, Feria-Romero I, Orozco-Suárez S. Factors not considered in the study of drug-resistant epilepsy: Drug-resistant epilepsy: Assessment of neuroinflammation. Epilepsia Open. 2022; 7 Suppl 1(Suppl 1): S68–S80.
    CrossRefPubMed
  6. Chen Yu, Nagib MM, Yasmen N, et al. Neuroinflammatory mediators in acquired epilepsy: an update. Inflamm Res. 2023; 72(4): 683–701.
    CrossRefPubMed
  7. Iyer A, Zurolo E, Spliet WGM, et al. Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias. Epilepsia. 2010; 51(9): 1763–1773.
    CrossRefPubMed
  8. Crespel A, Coubes P, Rousset MC, et al. Inflammatory reactions in human medial temporal lobe epilepsy with hippocampal sclerosis. Brain Res. 2002; 952(2): 159–169.
    CrossRefPubMed
  9. Boer K, Crino PB, Gorter JA, et al. Gene expression analysis of tuberous sclerosis complex cortical tubers reveals increased expression of adhesion and inflammatory factors. Brain Pathol. 2010; 20(4): 704–719.
    CrossRefPubMed
  10. Maldonado M, Baybis M, Newman D, et al. Expression of ICAM-1, TNF-alpha, NF kappa B, and MAP kinase in tubers of the tuberous sclerosis complex. Neurobiol Dis. 2003; 14(2): 279–290.
    CrossRefPubMed
  11. Lorigados Pedre L, Morales Chacón LM, Pavón Fuentes N, et al. Follow-Up of Peripheral IL-1β and IL-6 and Relation with Apoptotic Death in Drug-Resistant Temporal Lobe Epilepsy Patients Submitted to Surgery. Behav Sci (Basel). 2018; 8(2).
    CrossRefPubMed
  12. Li W, Wu J, Zeng Y, et al. Neuroinflammation in epileptogenesis: from pathophysiology to therapeutic strategies. Front Immunol. 2023; 14: 1269241.
    CrossRefPubMed
  13. Mukhtar I. Inflammatory and immune mechanisms underlying epileptogenesis and epilepsy: From pathogenesis to treatment target. Seizure. 2020; 82: 65–79.
    CrossRefPubMed
  14. Ma H, Lin H. Advances regarding Neuroinflammation Biomarkers with Noninvasive Techniques in Epilepsy. Behav Neurol. 2021; 2021: 7946252.
    CrossRefPubMed
  15. Du Y, Li R, Fu D, et al. Multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy. CNS Neurosci Ther. 2024; 30(4): e14717.
    CrossRefPubMed
  16. Srivastava A, Dixit AB, Banerjee J, et al. Role of inflammation and its miRNA based regulation in epilepsy: Implications for therapy. Clin Chim Acta. 2016; 452: 1–9.
    CrossRefPubMed
  17. Löscher W, Friedman A. Structural, Molecular, and Functional Alterations of the Blood-Brain Barrier during Epileptogenesis and Epilepsy: A Cause, Consequence, or Both? Int J Mol Sci. 2020; 21(2).
    CrossRefPubMed
  18. Lischper M, Beuck S, Thanabalasundaram G, et al. Metalloproteinase mediated occludin cleavage in the cerebral microcapillary endothelium under pathological conditions. Brain Res. 2010; 1326: 114–127.
    CrossRefPubMed
  19. Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013; 19(12): 1584–1596.
    CrossRefPubMed
  20. Varvel NH, Neher JJ, Bosch A, et al. Infiltrating monocytes promote brain inflammation and exacerbate neuronal damage after status epilepticus. Proc Natl Acad Sci U S A. 2016; 113(38): E5665–E5674.
    CrossRefPubMed
  21. Fabene PF, Navarro Mora G, Martinello M, et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat Med. 2008; 14(12): 1377–1383.
    CrossRefPubMed
  22. Reiter JT, Schulte F, Bauer T, et al. Evidence for interictal blood-brain barrier dysfunction in people with epilepsy. Epilepsia. 2024; 65(5): 1462–1474.
    CrossRefPubMed
  23. Rüber T, David B, Lüchters G, et al. Evidence for peri-ictal blood-brain barrier dysfunction in patients with epilepsy. Brain. 2018; 141(10): 2952–2965.
    CrossRefPubMed
  24. Hanael E, Veksler R, Friedman A, et al. Blood-brain barrier dysfunction in canine epileptic seizures detected by dynamic contrast-enhanced magnetic resonance imaging. Epilepsia. 2019; 60(5): 1005–1016.
    CrossRefPubMed
  25. Mendes NF, Pansani AP, Carmanhães ER, et al. The Blood-Brain Barrier Breakdown During Acute Phase of the Pilocarpine Model of Epilepsy Is Dynamic and Time-Dependent. Front Neurol. 2019; 10: 382.
    CrossRefPubMed
  26. Dannhauser D, Rossi D, De Gregorio V, et al. Single cell classification of macrophage subtypes by label-free cell signatures and machine learning. R Soc Open Sci. 2022; 9(9): 220270.
    CrossRefPubMed
  27. Devinsky O, Vezzani A, Najjar S, et al. Glia and epilepsy: excitability and inflammation. Trends Neurosci. 2013; 36(3): 174–184.
    CrossRefPubMed
  28. Yu C, Deng XJ, Xu Da. Microglia in epilepsy. Neurobiol Dis. 2023; 185: 106249.
    CrossRefPubMed
  29. Sun H, Ma Di, Cheng Yu, et al. The JAK-STAT Signaling Pathway in Epilepsy. Curr Neuropharmacol. 2023; 21(10): 2049–2069.
    CrossRefPubMed
  30. Maroso M, Balosso S, Ravizza T, et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med. 2010; 16(4): 413–419.
    CrossRefPubMed
  31. Jangde N, Ray R, Rai V. RAGE and its ligands: from pathogenesis to therapeutics. Crit Rev Biochem Mol Biol. 2020; 55(6): 555–575.
    CrossRefPubMed
  32. Walker LE, Sills GJ, Jorgensen A, et al. High-mobility group box 1 as a predictive biomarker for drug-resistant epilepsy: A proof-of-concept study. Epilepsia. 2022; 63(1): e1–e6.
    CrossRefPubMed
  33. Fu Li, Liu K, Wake H, et al. Therapeutic effects of anti-HMGB1 monoclonal antibody on pilocarpine-induced status epilepticus in mice. Sci Rep. 2017; 7(1): 1179.
    CrossRefPubMed
  34. Paudel YN, Angelopoulou E, Akyuz E, et al. Role of Innate Immune Receptor TLR4 and its endogenous ligands in epileptogenesis. Pharmacol Res. 2020; 160: 105172.
    CrossRefPubMed
  35. Zhu X, Liu J, Chen Ou, et al. Neuroprotective and anti-inflammatory effects of isoliquiritigenin in kainic acid-induced epileptic rats via the TLR4/MYD88 signaling pathway. Inflammopharmacology. 2019; 27(6): 1143–1153.
    CrossRefPubMed
  36. Hu QP, Mao DA. Histone deacetylase inhibitor SAHA attenuates post-seizure hippocampal microglia TLR4/MYD88 signaling and inhibits TLR4 gene expression via histone acetylation. BMC Neurosci. 2016; 17(1): 22.
    CrossRefPubMed
  37. Pernhorst K, Herms S, Hoffmann P, et al. TLR4, ATF-3 and IL8 inflammation mediator expression correlates with seizure frequency in human epileptic brain tissue. Seizure. 2013; 22(8): 675–678.
    CrossRefPubMed
  38. Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018; 281(1): 8–27.
    CrossRefPubMed
  39. Dong Y, Zhang X, Wang Y. Interleukins in Epilepsy: Friend or Foe. Neurosci Bull. 2024; 40(5): 635–657.
    CrossRefPubMed
  40. Shi LM, Chen RJ, Zhang H, et al. Cerebrospinal fluid neuron specific enolase, interleukin-1β and erythropoietin concentrations in children after seizures. Childs Nerv Syst. 2017; 33(5): 805–811.
    CrossRefPubMed
  41. Soltani Khaboushan A, Yazdanpanah N, Rezaei N. Neuroinflammation and Proinflammatory Cytokines in Epileptogenesis. Mol Neurobiol. 2022; 59(3): 1724–1743.
    CrossRefPubMed
  42. Rana A, Musto AE. The role of inflammation in the development of epilepsy. J Neuroinflammation. 2018; 15(1): 144.
    CrossRefPubMed
  43. Santos RO, Secolin R, Barbalho PG, et al. Multidimensional Approach Assessing the Role of Interleukin 1 Beta in Mesial Temporal Lobe Epilepsy. Front Neurol. 2021; 12: 690847.
    CrossRefPubMed
  44. Aledo-Serrano A, Hariramani R, Gonzalez-Martinez A, et al. Anakinra and tocilizumab in the chronic phase of febrile infection-related epilepsy syndrome (FIRES): Effectiveness and safety from a case-series. Seizure. 2022; 100: 51–55.
    CrossRefPubMed
  45. Girardin ML, Flamand T, Roignot O, et al. Treatment of new onset refractory status epilepticus/febrile infection-related epilepsy syndrome with tocilizumab in a child and a young adult. Epilepsia. 2023; 64(6): e87–e92.
    CrossRefPubMed
  46. Ethemoglu O, Calık M, Koyuncu I, et al. Interleukin-33 and oxidative stress in epilepsy patients. Epilepsy Res. 2021; 176: 106738.
    CrossRefPubMed
  47. Grebenciucova E, VanHaerents S. Interleukin 6: at the interface of human health and disease. Front Immunol. 2023; 14: 1255533.
    CrossRefPubMed
  48. Fang W, Chen S, Xia X, et al. Interictal interleukin-6 and tumor necrosis factor α levels are associated with seizure recurrence in adults with epilepsy. Epilepsy Behav. 2024; 155: 109786.
    CrossRefPubMed
  49. Alyu F, Dikmen M. Inflammatory aspects of epileptogenesis: contribution of molecular inflammatory mechanisms. Acta Neuropsychiatr. 2017; 29(1): 1–16.
    CrossRefPubMed
  50. Steinborn B, Zarowski M, Winczewska-Wiktor A, et al. Concentration of Il-1β, Il-2, Il-6, TNFα in the blood serum in children with generalized epilepsy treated by valproate. Pharmacol Rep. 2014; 66(6): 972–975.
    CrossRefPubMed
  51. Česká K, Papež J, Ošlejšková H, et al. CCL2/MCP-1, interleukin-8, and fractalkine/CXC3CL1: Potential biomarkers of epileptogenesis and pharmacoresistance in childhood epilepsy. Eur J Paediatr Neurol. 2023; 46: 48–54.
    CrossRefPubMed
  52. Asano T, Ichiki K, Koizumi S, et al. IL-8 in cerebrospinal fluid from children with acute encephalopathy is higher than in that from children with febrile seizure. Scand J Immunol. 2010; 71(6): 447–451.
    CrossRefPubMed
  53. Lim JA, Lee ST, Moon J, et al. New feasible treatment for refractory autoimmune encephalitis: Low-dose interleukin-2. J Neuroimmunol. 2016; 299: 107–111.
    CrossRefPubMed
  54. Mazumder AG, Patial V, Singh D. Mycophenolate mofetil contributes to downregulation of the hippocampal interleukin type 2 and 1β mediated PI3K/AKT/mTOR pathway hyperactivation and attenuates neurobehavioral comorbidities in a rat model of temporal lobe epilepsy. Brain Behav Immun. 2019; 75: 84–93.
    CrossRefPubMed
  55. Guo W, Zheng DH, Sun FJ, et al. Expression and cellular distribution of the interleukin 2 signaling system in cortical lesions from patients with focal cortical dysplasia. J Neuropathol Exp Neurol. 2014; 73(3): 206–222.
    CrossRefPubMed
  56. Gadani SP, Cronk JC, Norris GT, et al. IL-4 in the brain: a cytokine to remember. J Immunol. 2012; 189(9): 4213–4219.
    CrossRefPubMed
  57. Radpour M, Khoshkroodian B, Asgari T, et al. Interleukin 4 Reduces Brain Hyperexcitability after Traumatic Injury by Downregulating TNF-α, Upregulating IL-10/TGF-β, and Potential Directing Macrophage/Microglia to the M2 Anti-inflammatory Phenotype. Inflammation. 2023; 46(5): 1810–1831.
    CrossRefPubMed
  58. Sun FJ, Zhang CQ, Chen X, et al. Downregulation of CD47 and CD200 in patients with focal cortical dysplasia type IIb and tuberous sclerosis complex. J Neuroinflammation. 2016; 13(1): 85.
    CrossRefPubMed
  59. Ouyang W, O'Garra A. IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation. Immunity. 2019; 50(4): 871–891.
    CrossRefPubMed
  60. Ruffolo G, Alfano V, Romagnolo A, et al. GABA receptor function is enhanced by Interleukin-10 in human epileptogenic gangliogliomas and its effect is counteracted by Interleukin-1β. Sci Rep. 2022; 12(1): 17956.
    CrossRefPubMed
  61. Cerri C, Caleo M, Bozzi Y. Chemokines as new inflammatory players in the pathogenesis of epilepsy. Epilepsy Res. 2017; 136: 77–83.
    CrossRefPubMed
  62. Kothur K, Bandodkar S, Wienholt L, et al. Etiology is the key determinant of neuroinflammation in epilepsy: Elevation of cerebrospinal fluid cytokines and chemokines in febrile infection-related epilepsy syndrome and febrile status epilepticus. Epilepsia. 2019; 60(8): 1678–1688.
    CrossRefPubMed
  63. Meng F, Yao L. The role of inflammation in epileptogenesis. Acta Epileptologica. 2020; 2(1).
    CrossRef
  64. Sinha S, Patil SA, Jayalekshmy V, et al. Do cytokines have any role in epilepsy? Epilepsy Res. 2008; 82(2-3): 171–176.
    CrossRefPubMed
  65. Lagarde S, Villeneuve N, Trébuchon A, et al. Anti-tumor necrosis factor alpha therapy (adalimumab) in Rasmussen's encephalitis: An open pilot study. Epilepsia. 2016; 57(6): 956–966.
    CrossRefPubMed
  66. Luo X, Li D, Cen D, et al. Effect of intravenous immunoglobulin treatment on brain interferon-gamma and interleukin-6 levels in a rat kindling model. Epilepsy Res. 2010; 88(2-3): 162–167.
    CrossRefPubMed
  67. Gao F, Gao Y, Zhang SJ, et al. Alteration of plasma cytokines in patients with active epilepsy. Acta Neurol Scand. 2017; 135(6): 663–669.
    CrossRefPubMed
  68. Luo J. TGF-β as a Key Modulator of Astrocyte Reactivity: Disease Relevance and Therapeutic Implications. Biomedicines. 2022; 10(5).
    CrossRefPubMed
  69. Yu W, Zou Y, Du Y, et al. Altered cerebrospinal fluid concentrations of TGFβ1 in patients with drug-resistant epilepsy. Neurochem Res. 2014; 39(11): 2211–2217.
    CrossRefPubMed
  70. Zheng Z, Yan Y, Guo Qi, et al. Genetic Interaction of and Polymorphisms with Risk of Epilepsy in a Chinese Population. Pharmgenomics Pers Med. 2021; 14: 77–86.
    CrossRefPubMed
  71. Ivens S, Kaufer D, Flores LP, et al. TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis. Brain. 2007; 130(Pt 2): 535–547.
    CrossRefPubMed
  72. Cacheaux LP, Ivens S, David Y, et al. Transcriptome profiling reveals TGF-beta signaling involvement in epileptogenesis. J Neurosci. 2009; 29(28): 8927–8935.
    CrossRefPubMed
  73. Bar-Klein G, Cacheaux LP, Kamintsky L, et al. Losartan prevents acquired epilepsy via TGF-β signaling suppression. Ann Neurol. 2014; 75(6): 864–875.
    CrossRefPubMed
  74. Weissberg I, Wood L, Kamintsky L, et al. Albumin induces excitatory synaptogenesis through astrocytic TGF-β/ALK5 signaling in a model of acquired epilepsy following blood-brain barrier dysfunction. Neurobiol Dis. 2015; 78: 115–125.
    CrossRefPubMed
  75. Shimada T, Takemiya T, Sugiura H, et al. Role of inflammatory mediators in the pathogenesis of epilepsy. Mediators Inflamm. 2014; 2014: 901902.
    CrossRefPubMed
  76. Warwick CA, Keyes AL, Woodruff TM, et al. The complement cascade in the regulation of neuroinflammation, nociceptive sensitization, and pain. J Biol Chem. 2021; 297(3): 101085.
    CrossRefPubMed
  77. Kobylarek D, Iwanowski P, Lewandowska Z, et al. Advances in the Potential Biomarkers of Epilepsy. Front Neurol. 2019; 10: 685.
    CrossRefPubMed
  78. Başaran N, Hincal F, Kansu E, et al. Humoral and cellular immune parameters in untreated and phenytoin-or carbamazepine-treated epileptic patients. Int J Immunopharmacol. 1994; 16(12): 1071–1077.
    CrossRefPubMed
  79. Liguori C, Romigi A, Izzi F, et al. Complement system dysregulation in patients affected by Idiopathic Generalized Epilepsy and the effect of antiepileptic treatment. Epilepsy Res. 2017; 137: 107–111.
    CrossRefPubMed
  80. Wyatt SK, Witt T, Barbaro NM, et al. Enhanced classical complement pathway activation and altered phagocytosis signaling molecules in human epilepsy. Exp Neurol. 2017; 295: 184–193.
    CrossRefPubMed
  81. Jamali S, Salzmann A, Perroud N, et al. Functional variant in complement C3 gene promoter and genetic susceptibility to temporal lobe epilepsy and febrile seizures. PLoS One. 2010; 5(9).
    CrossRefPubMed
  82. Aronica E, Boer K, van Vliet EA, et al. Complement activation in experimental and human temporal lobe epilepsy. Neurobiol Dis. 2007; 26(3): 497–511.
    CrossRefPubMed
  83. Kopczynska M, Zelek WM, Vespa S, et al. Complement system biomarkers in epilepsy. Seizure. 2018; 60: 1–7.
    CrossRefPubMed
  84. Fu M, Tao J, Wang D, et al. Downregulation of MicroRNA-34c-5p facilitated neuroinflammation in drug-resistant epilepsy. Brain Res. 2020; 1749: 147130.
    CrossRefPubMed
  85. Lu J, Zhou N, Yang P, et al. MicroRNA-27a-3p Downregulation Inhibits Inflammatory Response and Hippocampal Neuronal Cell Apoptosis by Upregulating Mitogen-Activated Protein Kinase 4 (MAP2K4) Expression in Epilepsy: In Vivo and In Vitro Studies. Med Sci Monit. 2019; 25: 8499–8508.
    CrossRefPubMed
  86. Ashhab MU, Omran A, Kong H, et al. Expressions of tumor necrosis factor alpha and microRNA-155 in immature rat model of status epilepticus and children with mesial temporal lobe epilepsy. J Mol Neurosci. 2013; 51(3): 950–958.
    CrossRefPubMed
  87. Zhang H, Qu Y, Wang A. Antagonist targeting microRNA 146a protects against lithium-pilocarpine-induced status epilepticus in rats by nuclear factor-B pathway. Mol. Med. Rep. 2018; 17(4): 5356–5361.
    CrossRefPubMed
  88. Tao H, Zhao J, Liu T, et al. Intranasal Delivery of miR-146a Mimics Delayed Seizure Onset in the Lithium-Pilocarpine Mouse Model. Mediators Inflamm. 2017; 2017: 6512620.
    CrossRefPubMed
  89. Fu M, Tao J, Wang D, et al. Downregulation of MicroRNA-34c-5p facilitated neuroinflammation in drug-resistant epilepsy. Brain Res. 2020; 1749: 147130.
    CrossRefPubMed
  90. Costagliola G, Depietri G, Michev A, et al. Targeting Inflammatory Mediators in Epilepsy: A Systematic Review of Its Molecular Basis and Clinical Applications. Front Neurol. 2022; 13: 741244.
    CrossRefPubMed
  91. Zhao L, Murray S, Mariani LH, et al. Incorporating longitudinal biomarkers for dynamic risk prediction in the era of big data: A pseudo-observation approach. Stat Med. 2020; 39(26): 3685–3699.
    CrossRefPubMed
  92. Ma H, Lin H. Advances regarding Neuroinflammation Biomarkers with Noninvasive Techniques in Epilepsy. Behav Neurol. 2021; 2021: 7946252.
    CrossRefPubMed
  93. Ng S, Masarone S, Watson D, et al. The benefits and pitfalls of machine learning for biomarker discovery. Cell Tissue Res. 2023; 394(1): 17–31.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2025 Via Medica Regulations Cookie policy Privacy Statement Legal Note